Clinical Trials Update: Sept. 6, 2006

Depression or Depression (Major/Severe) Non-Small Cell Lung Cancer Premature Ejaculation

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Depression or Depression (Major/Severe)

This clinical research study will evaluate an experimental drug for its safety and effectiveness in treating major depressive disorder. You may be eligible to participate if you are between 18 and 65 and have symptoms of depression including lack of energy, trouble sleeping, or difficulty concentrating.

The research site is in Atlanta, Ga.

More information

Please see http://www.centerwatch.com/patient/studies/cat164.html or http://www.centerwatch.com/patient/studies/cat97.html.

-----

Non-Small Cell Lung Cancer

This study will evaluate the effectiveness of Tarceva vs. inactive placebo for stage IB-IIIA NSCLC patients with a primary EGFR-positive tumor that has been surgically removed. Volunteers 18 or older with a complete removal of EGFR-positive tumor by surgery, confirmed diagnosis of Stage IB-IIIA NSCLC, and who had up to four cycles of chemotherapy after surgery may qualify. Patients with carcinoid tumors or with tumors with mixed histology of NSCLC and SCLC are not eligible.

The research sites are located across the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat683.html.

-----

Premature Ejaculation

This nine-week clinical research study will evaluate the safety and effectiveness of an investigational medication for premature ejaculation. Candidates 18-55 who regularly have premature ejaculation and are in a stable relationship with one female partner for at least six months may qualify.

The research sites are located across the United States.

More information

Please see http://www.centerwatch.com/patient/studies/cat123.html.

-----

Copyright 2006 Thomson CenterWatch. All rights reserved.

Related Stories

No stories found.
logo
www.healthday.com